Quercetin loading on mesoporous magnetic MnFe2O4@ hydroxyapatite core-shell nanoparticles for treating cancer cells

Despite the availability of various nanostructure for cancer cells therapeutic, caring hydrophobic drugs to the target site is still one of the great challenges in chemotherapy. In this study, quercetin (QC), a poorly water-soluble natural anticancer agent, was used as a model drug to evaluate the efficiency of mesoporous magnetic MnFe(2)O(4 )core-shell nanocomposite particles. A simple co-precipitation method was employed to synthesis MnFe(2)O(4 )as core of nanostructure. Then, the obtained MnFe(2)O(4 )nanoparticles were coated with mesoporous hydroxyapatite (HA) shell as a new perspective for drug loading. The magnetic mesoporous nanostructure had specific surface area and mean pore size of 165.44 m(2)/g and 11.561 nm, respectively. In QC loading process, the MnFe2O4@HA nanostructure demonstrated loading capacity of 123 lg/mg with pH-depended release manner. In compare with free QC, loaded QC on MnFe(2)O(4 )core-shell nanocomposite particles exhibited 55% higher antioxidant activities against free 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. Moreover, comparative in-vitro anticancer studies on Michigan cancer foundation (MCF)-7 cells, breast cancer cell line, demonstrated more reduction in number of viable cells (35.6%) using loaded QC than that of free QC (50.76%), suggesting improvement in the solubility of QC by loading onto mesoporous magnetic nanocomposite particles compared to free QC. (C) 2022 The Society of Powder Technology Japan. Published by Elsevier BV and The Society of Powder Technology Japan. All rights reserved.

Automated summary

This study evaluated the efficiency of mesoporous magnetic MnFe(2)O(4) core-shell nanocomposite particles for delivering the poorly water-soluble anticancer agent quercetin (QC). The results showed that loading QC onto the nanoparticles improved its solubility and antioxidant activities. The study suggests that this new nanostructure has potential applications in cancer cell therapy.